TL;DR
Get beauty and skincare favorites delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Amorepacific Ventures has invested in biotechnology company Junevity and signed a separate licensing agreement covering cosmetic applications of Junevity’s technology. The companies plan to research skin-ageing pathways; product candidates, timelines and investment terms have not been disclosed.
Amorepacific Ventures, the corporate investment arm of South Korean beauty company Amorepacific, has invested in biotechnology firm Junevity and signed a separate licensing agreement for cosmetic applications of Junevity’s technology. The companies say they will use Junevity’s RESET Platform and Amorepacific’s skin-science and product-development capabilities to investigate skin-ageing pathways that could inform future cosmetics.
The collaboration is focused on identifying biological pathways with potential relevance to cosmetic products. According to the companies, Junevity will apply its RESET Platform and target-discovery capabilities to research skin ageing, while Amorepacific will contribute knowledge of skin biology, cosmetics development and commercialisation. Their stated aim is to explore whether skin gene networks can be directed toward what they describe as a healthier state.
The agreement has two distinct elements: a strategic investment by Amorepacific Ventures and a separate licensing arrangement covering cosmetic-field applications. The source report does not state the size or terms of the investment, or specify the licensed technology, exclusivity, or geographic scope. It also does not identify a product candidate or say that a finished product is in development.
Under the companies’ division of responsibilities, Amorepacific will lead cosmetic development and commercialisation. Junevity will continue advancing therapeutic applications of its platform, according to its chief executive. The collaboration is therefore aimed at applying the platform in cosmetics while the biotech firm maintains work on its separate therapeutic pipeline.
A Biotech Route Into Skin Care Research
The deal connects a cosmetics company’s research and commercial capabilities with a biotechnology platform designed to identify biological targets. For Amorepacific, the partnership offers a route to investigate skin ageing at the level of gene networks and transcriptional regulation, rather than relying only on conventional ingredient or formulation development. That is the stated research direction, not evidence that the companies have already found an effective cosmetic intervention.
For Junevity, the licensing agreement gives its platform a potential application in the cosmetics market, alongside the therapeutic work it says it will continue. The arrangement also separates the partners’ roles: Amorepacific is responsible for bringing any resulting cosmetic products to market, while Junevity continues its therapeutic programme. Whether that research produces products, and whether consumers will see them as distinct from existing skin-care offerings, remains unknown.
The announcement comes as beauty companies explore longevity-related language and science. In this case, the companies describe a research collaboration focused on pathways associated with skin ageing. Readers should distinguish that ambition from demonstrated results: the announcement provides no clinical or consumer data, no efficacy claims supported by study findings, and no confirmed launch plans.
As an affiliate, we earn on qualifying purchases.
How the Companies Plan to Collaborate
Amorepacific is the parent company of beauty brands including Laneige. Its corporate venture arm, Amorepacific Ventures, made the investment described in the report. The parent company’s role in the partnership extends beyond funding: it is also expected to contribute skin biology expertise and take responsibility for cosmetic development and commercialisation.
Junevity describes its RESET Platform as a target-discovery engine. In the collaboration, the platform is intended to help identify pathways connected to skin ageing that may be relevant to cosmetics. The partners say the research will examine gene networks and transcriptional regulation. Those terms refer to systems involved in how genes are controlled; the report does not provide technical details about the platform’s methods or disclose which targets are being studied.
Junevity’s work also includes therapeutic research. Its co-founder and chief executive referenced a lead small interfering RNA, or siRNA, candidate for obesity, which he said was headed toward human clinical trials. That programme is separate from the cosmetic collaboration. The source report did not provide a trial start date, study design or results, so the reference should not be read as evidence about the skin-care research.
“The next-generation of skin health innovations will be informed by deeper research-driven insights into the biology of skin ageing, particularly the role of gene networks and transcriptional regulation in longevity.”
— Brian Byung-Fhy Suh, CTO of Amorepacific’s R&I Center
Investment Terms and Product Timing
The available report does not disclose the investment amount, the licensing fee or other financial terms, or whether the cosmetics licence is exclusive. It also gives no research schedule, named biological targets, product formulation, regulatory plan or anticipated launch date.
It is not yet clear whether the work has moved beyond an initial research collaboration, how the partners will evaluate possible cosmetic applications, or what evidence would be required before any product claims are made. The companies’ stated goal of resetting or rejuvenating skin gene networks is an intended research objective; the announcement does not establish that such an effect has been achieved in people or that a product can deliver it.
Research Before Any Product Launch
The immediate next step described by the companies is joint research using Junevity’s platform and Amorepacific’s skin-science capabilities to identify pathways that may be suitable for cosmetic applications. If the partners identify viable directions, Amorepacific is expected to lead development and commercialisation, while Junevity continues its therapeutic programmes.
No public milestone dates were provided. Further updates would be needed to establish which pathways are selected, whether the research generates a specific cosmetic candidate, what testing is planned, and when any product might reach the market. Until those details emerge, the announcement represents an investment and research partnership rather than a product launch.
Key Questions
What did Amorepacific invest in?
Amorepacific Ventures made a strategic investment in biotechnology firm Junevity. The amount and other financial terms were not reported.
What will the companies research?
They plan to study skin-ageing pathways using Junevity’s RESET Platform alongside Amorepacific’s skin biology and cosmetics expertise. The partners have not named specific targets.
Is a new skin-care product confirmed?
No product, formulation or launch date has been announced. The companies describe a research collaboration intended to inform possible future cosmetic development.
Who would develop and sell any resulting cosmetics?
According to the announcement, Amorepacific will lead cosmetic development and commercialisation. Junevity will continue advancing therapeutic applications of its platform.
What remains unknown about the deal?
The report does not provide the investment value, licensing terms, research timetable, selected biological targets, testing plans or expected product timeline. It also reports no evidence that the proposed skin effects have been achieved.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
